Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Clinical Significance of the IL-33-ACOD1-MARCO Axis in HBV-Related Acute-on-Chronic Liver Failure

15 novembre 2026 aggiornato da: Minghui Li

The IL-33-ACOD1-MARCO Axis in Ameliorating Immune-Mediated Liver Injury and Its Clinical Significance in HBV-Related Acute-on-Chronic Liver Failure

This single-center, prospective observational study will enroll 80 adults: 15 healthy controls, 20 participants with chronic hepatitis B, 20 participants with HBV-related cirrhosis, and 25 participants with HBV-related acute-on-chronic liver failure (HBV-ACLF). The study will not assign any research treatment, and all participants will continue to receive routine clinical care. A 5 mL peripheral blood sample will be collected once from the first three groups. Participants with HBV-ACLF will have 5 mL blood collected at baseline, Day 28, and Day 90, and their 28-day and 90-day survival status will be recorded. Plasma IL-33, IL-6, TNF-alpha, and IL-10 will be measured. Peripheral blood CD14-positive monocytes will be isolated, and ACOD1 and MARCO mRNA expression will be measured by quantitative PCR. The study will compare these markers across groups and assess their relationships with inflammation, disease severity, longitudinal clinical changes, and short-term outcomes.

Panoramica dello studio

Descrizione dettagliata

HBV-related acute-on-chronic liver failure is characterized by rapid clinical deterioration, systemic inflammation, and high short-term mortality. Previous experimental work in a mouse model of immune-mediated liver injury suggested that IL-33 may induce ACOD1 expression in hepatic macrophages and increase MARCO expression through an itaconate-related pathway, thereby enhancing efferocytosis and reducing inflammatory injury. The complete IL-33-ACOD1-MARCO axis has not been established in patients, and measurements in peripheral blood CD14-positive monocytes cannot be considered direct measurements of liver-resident macrophage function.

This study combines a cross-sectional comparison with longitudinal follow-up. At baseline, plasma IL-33 and inflammatory cytokines and CD14-positive monocyte ACOD1 and MARCO mRNA expression will be compared among healthy controls, participants with chronic hepatitis B, participants with HBV-related cirrhosis, and participants with HBV-ACLF. In the HBV-ACLF group, associations with Model for End-Stage Liver Disease (MELD) score, COSSH-ACLF score, IL-6, TNF-alpha, and IL-10 will be evaluated. Participants with HBV-ACLF will undergo follow-up at Day 28 and Day 90 to assess biomarker changes, all-cause mortality, and liver transplantation status.

Blood will be collected in EDTA-K2 tubes and processed within 2 hours. Plasma IL-33 will be measured by ELISA, and IL-6, TNF-alpha, and IL-10 will be measured by Luminex. Peripheral blood mononuclear cells will be isolated by Ficoll density-gradient centrifugation, followed by CD14-positive magnetic-bead selection and flow-cytometric verification of purity. ACOD1 and MARCO mRNA expression will be measured by quantitative PCR using GAPDH as the reference gene and the 2^-DeltaDeltaCt method.

Tipo di studio

Osservativo

Iscrizione (Stimato)

80

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Beijing Municipality
      • Beijing, Beijing Municipality, Cina, 100015
        • : Beijing Ditan Hospital, Capital Medical University
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 70 anni (Adulto, Adulto più anziano)

Accetta volontari sani

N/A

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

Adults aged 18 to 70 years will be recruited at Beijing Ditan Hospital, Capital Medical University. The study population will include healthy individuals undergoing routine health examinations and patients receiving care at the Liver Disease Center for chronic hepatitis B, HBV-related cirrhosis, or HBV-related acute-on-chronic liver failure. Individuals who meet the applicable group definition and the inclusion and exclusion criteria will be enrolled after providing written informed consent. The planned enrollment is 15 healthy controls, 20 participants with chronic hepatitis B, 20 participants with HBV-related cirrhosis, and 25 participants with HBV-ACLF.

Descrizione

Inclusion Criteria:

  • Aged 18 to 70 years, regardless of sex.
  • Meets the criteria for one of the following study groups:

Healthy Control Group: No history of liver disease, negative hepatitis B surface antigen (HBsAg), and normal liver function.

Chronic Hepatitis B Group: HBsAg positivity for more than 6 months, no imaging evidence of cirrhosis, and does not meet the diagnostic criteria for HBV-related acute-on-chronic liver failure (HBV-ACLF).

HBV-Related Cirrhosis Group: HBsAg positivity for more than 6 months and cirrhosis confirmed by imaging or pathological examination, without meeting the diagnostic criteria for HBV-ACLF.

HBV-ACLF Group: HBsAg positivity for more than 6 months and meets the COSSH-ACLF diagnostic criteria.

-Fully understands the study and voluntarily provides written informed consent.

Exclusion Criteria:

  • Coinfection with hepatitis A, C, D, or E virus, or the presence of another liver disease, including autoimmune liver disease, drug-induced liver injury, or alcohol-related liver disease.
  • Confirmed hepatocellular carcinoma.
  • Pregnancy or breastfeeding.
  • Treatment with immunosuppressive agents or high-dose glucocorticoids within 4 weeks before enrollment.
  • Human immunodeficiency virus infection.
  • Severe renal impairment, defined as an estimated glomerular filtration rate below 30 mL/min/1.73 m².
  • Incomplete key clinical data at enrollment or an anticipated inability to complete the study sampling and follow-up required for the assigned group.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: COHORT
  • Prospettive temporali: PROSPECTIVE

Coorti e interventi

Gruppo / Coorte
Healthy Control

Adults without a history of liver disease, with negative hepatitis B surface antigen and normal liver function. Participants will undergo one study blood collection at enrollment.

Chronic Hepatitis B

Adults with hepatitis B surface antigen positivity for more than 6 months, without imaging evidence of cirrhosis and not meeting the COSSH-ACLF diagnostic criteria. Participants will undergo one baseline study blood collection.

HBV-Related Cirrhosis

Adults with chronic HBV infection and cirrhosis confirmed by imaging or pathology, without meeting the COSSH-ACLF diagnostic criteria. Participants will undergo one baseline study blood collection.

HBV-Related Acute-on-Chronic Liver Failure

Adults with hepatitis B surface antigen positivity for more than 6 months who meet the COSSH-ACLF diagnostic criteria. Participants will undergo study blood collection at baseline, Day 28, and Day 90 and will be followed for 28-day and 90-day survival outcomes.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Plasma IL-33 Concentration at Baseline Across Study Groups
Lasso di tempo: Baseline (at enrollment or hospital admission)

Plasma IL-33 concentration will be measured in EDTA plasma by enzyme-linked immunosorbent assay (ELISA) in healthy controls, participants with chronic hepatitis B, participants with HBV-related cirrhosis, and participants with HBV-related acute-on-chronic liver failure.

Baseline (at enrollment or hospital admission)
ACOD1 mRNA Expression in Peripheral Blood CD14-Positive Monocytes at Baseline Across Study Groups
Lasso di tempo: Baseline (at enrollment or hospital admission)

Peripheral blood mononuclear cells will be isolated and CD14-positive monocytes will be selected using magnetic beads. ACOD1 mRNA expression will be measured by quantitative PCR, with GAPDH as the reference gene, and reported as relative expression calculated using the 2^-DeltaDeltaCt method.

Baseline (at enrollment or hospital admission)
MARCO mRNA Expression in Peripheral Blood CD14-Positive Monocytes at Baseline Across Study Groups
Lasso di tempo: Baseline (at enrollment or hospital admission)

Peripheral blood mononuclear cells will be isolated and CD14-positive monocytes will be selected using magnetic beads. MARCO mRNA expression will be measured by quantitative PCR, with GAPDH as the reference gene, and reported as relative expression calculated using the 2^-DeltaDeltaCt method.

Baseline (at enrollment or hospital admission)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Correlation of Plasma IL-33 With ACOD1 and MARCO mRNA Expression in Participants With HBV-ACLF
Lasso di tempo: Baseline

At baseline in participants with HBV-related acute-on-chronic liver failure, Spearman correlation coefficients will be calculated between plasma IL-33 concentration and ACOD1 and MARCO mRNA relative expression in peripheral blood CD14-positive monocytes.

Baseline
Association of ACOD1 and MARCO mRNA Expression With Disease Severity and Inflammatory Markers in Participants With HBV-ACLF
Lasso di tempo: Baseline

At baseline in participants with HBV-related acute-on-chronic liver failure, correlations of ACOD1 and MARCO mRNA relative expression with Model for End-Stage Liver Disease (MELD) score, COSSH-ACLF score, plasma IL-6, TNF-alpha, and IL-10 will be assessed.

Baseline
28-Day All-Cause Mortality in Participants With HBV-ACLF
Lasso di tempo: From baseline through Day 28

Vital status and date of death will be determined from medical records and, when necessary, telephone follow-up. Liver transplantation will be recorded separately and will not be counted as death.

From baseline through Day 28
90-Day All-Cause Mortality in Participants With HBV-ACLF
Lasso di tempo: From baseline through Day 90

Vital status and date of death will be determined from medical records and, when necessary, telephone follow-up. Liver transplantation will be recorded separately and will not be counted as death.

From baseline through Day 90
Change in Plasma IL-33 Concentration in Participants With HBV-ACLF
Lasso di tempo: Baseline, Day 28, and Day 90

Plasma IL-33 concentration will be measured by ELISA at baseline, Day 28, and Day 90. Within-participant changes over time will be described and analyzed using repeated-measures methods specified in the protocol.

Baseline, Day 28, and Day 90
Change in ACOD1 mRNA Expression in Peripheral Blood CD14-Positive Monocytes in Participants With HBV-ACLF
Lasso di tempo: Baseline, Day 28, and Day 90

ACOD1 mRNA relative expression in peripheral blood CD14-positive monocytes will be measured by quantitative PCR at baseline, Day 28, and Day 90, using GAPDH as the reference gene and the 2^-DeltaDeltaCt method.

Baseline, Day 28, and Day 90
Change in MARCO mRNA Expression in Peripheral Blood CD14-Positive Monocytes in Participants With HBV-ACLF
Lasso di tempo: Baseline, Day 28, and Day 90

MARCO mRNA relative expression in peripheral blood CD14-positive monocytes will be measured by quantitative PCR at baseline, Day 28, and Day 90, using GAPDH as the reference gene and the 2^-DeltaDeltaCt method.

Baseline, Day 28, and Day 90

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

30 novembre 2026

Completamento primario (Stimato)

31 maggio 2027

Completamento dello studio (Stimato)

31 ottobre 2027

Date di iscrizione allo studio

Primo inviato

15 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

15 novembre 2026

Primo Inserito (Effettivo)

19 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

19 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

15 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi